On 16 February 2023, Eurasanté successfully submitted, alongside its founding partners (Lille University Hospital, University of Lille, Clubster NSL, Centrale Lille, INSERM, Macopharma, Imabiotech, Mutuelle GSMC, Lesaffre, Roquette, Dedalus, Santélys) a collegial application for the second wave of the “BIOCLUSTER” Call for Expressions of Interest in the scope of the 2030 Health Innovation Plan.
More than ever, the Lille ecosystem believes in the future success of its “Eurasanté 2030” project, which brings together all the forces of industry, care, research and training within a single place to drive a Biocluster focused on the prevention and treatment of chronic diseases.
Effectively strengthening its application since the first submission in wave 1, the Lille project has brought together more than 120 partners and collected more than €150 million in private contributions, i.e. double the amount of private contributions posted by the Paris Saclay Cancer Cluster project, the sole winner of the first wave.
For more information: https://www.eurasante2030.com